Amylyx Pharmaceuticals (AMLX)

Company Profile

Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

Company profile

Ticker

AMLX

Exchange

Website

Incorporated

Location

Fiscal year end

Sector

Manufacturing > Medicinal and Botanical Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies ...

SEC CIK

0001658551

Corporate docs

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Amylyx Pharmaceuticals Canada Inc. • Amylyx Pharmaceuticals EMEA B.V. • Amylyx Pharmaceuticals Distribution Ltd. • Amylyx Pharmaceuticals Germany GmbH • Amylyx Pharmaceuticals France SAS ...

IRS number

464600503

AMLX stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$50.33

Low target

$47.00

High target

$54.00

Latest filings (excl ownership)

View all

8-K

Departure of Directors or Certain Officers

21 Mar 23

S-8

Registration of securities for employees

13 Mar 23

S-3ASR

Automatic shelf registration

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results

13 Mar 23

8-K

Regulation FD Disclosure

14 Feb 23

8-K

Entry into a Material Definitive Agreement

10 Nov 22

Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results

10 Nov 22

8-K

Departure of Directors or Certain Officers

2 Nov 22

Transcripts

AMLX

Earnings call transcript

2022 Q4

13 Mar 23

AMLX

Earnings call transcript

2022 Q3

13 Nov 22

Latest ownership filings

View all

Change in insider ownership

Change in insider ownership

Financial summary

Financial statements Chart AMLX financial data

Quarter (USD)	Dec 22	Sep 22	Jun 22	Mar 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	63.25 mm	63.25 mm	63.25 mm	63.25 mm		63.25 mm
Cash burn (monthly)	15.07 mm	(no burn)	14.86 mm	16.78 mm		3.39 mm
Cash used (since last report)	45.44 mm	n/a	44.82 mm	50.59 mm		10.21 mm
Cash remaining	17.81 mm	n/a	18.42 mm	12.65 mm		53.03 mm
Runway (months of cash)	1.2	n/a	1.2	0.8		15.7

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2022

AMLX institutional ownership history Ownership history

86.8% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	135	101	+33.7%
Opened positions	48	33	+45.5%
Closed positions	14	13	+7.7%
Increased positions	48	37	+29.7%
Reduced positions	32	21	+52.4%

13F shares	Current	Prev Q	Change
Total value	1.70 tn	1.28 bn	+132607.7%
Total shares	57.88 mm	45.74 mm	+26.5%
Total puts	224.50 k	1.46 mm	-84.7%
Total calls	470.10 k	2.53 mm	-81.4%
Total put/call ratio	0.5	0.6	-17.5%

Largest owners	Shares	Value	Change
Morningside Venture Investments	9.30 mm	$259.25 mm	0.0%
Perceptive Advisors	6.09 mm	$224.96 bn	+11.3%
Viking Global Investors	4.63 mm	$171.25 bn	-19.7%
Vanguard	4.36 mm	$161.05 bn	+24.0%
BLK Blackrock	3.62 mm	$133.65 bn	+57.5%
Deerfield Management	2.69 mm	$99.51 bn	NEW
Point72 Asset Management	2.13 mm	$78.63 bn	+355.7%
Boxer Capital	2.08 mm	$77.00 bn	0.0%
Adage Capital Partners GP, L.L.C.	1.91 mm	$70.54 bn	+41.4%
FHI Federated Hermes	1.61 mm	$59.67 bn	+21.5%

Largest transactions	Shares	Bought/sold	Change
Deerfield Management	2.69 mm	+2.69 mm	NEW
Point72 Asset Management	2.13 mm	+1.66 mm	+355.7%
BLK Blackrock	3.62 mm	+1.32 mm	+57.5%
D. E. Shaw & Co.	1.38 mm	+1.22 mm	+752.8%
Viking Global Investors	4.63 mm	-1.14 mm	-19.7%
Pictet Asset Management	1.12 mm	+1.12 mm	NEW
STT State Street	1.08 mm	+1.08 mm	NEW
Bain Capital Life Sciences Investors	0.00	-1.02 mm	EXIT
Vanguard	4.36 mm	+844.14 k	+24.0%
Rock Springs Capital Management	1.23 mm	+825.90 k	+204.6%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

AMLX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
28 Mar 23	Morningside Venture Investments	Common Stock	Sell	Dispose S	No	No	30.37	100,000	3.04 mm	7,026,350
27 Mar 23	Morningside Venture Investments	Common Stock	Sell	Dispose S	No	No	30.8	28,000	862.40 k	7,126,350
27 Mar 23	Morningside Venture Investments	Common Stock	Sell	Dispose S	No	No	30.25	32,964	997.16 k	7,154,350
21 Mar 23	Morningside Venture Investments	Common Stock	Sell	Dispose S	No	No	32.17	28,807	926.72 k	7,187,314
21 Mar 23	Morningside Venture Investments	Common Stock	Sell	Dispose S	No	No	31.69	34,641	1.10 mm	7,216,121
16 Mar 23	Morningside Venture Investments	Common Stock	Sell	Dispose S	No	No	32.55	9,122	296.92 k	7,250,762
16 Mar 23	James M Frates	Common Stock	Grant	Acquire A	No	No	0	21,667	0.00	23,176
16 Mar 23	James M Frates	Common Stock	Sell	Dispose S	No	Yes	32.4649	1,704	55.32 k	1,509
16 Mar 23	James M Frates	Common Stock	Sell	Dispose S	No	Yes	31.8593	30,796	981.14 k	3,213
16 Mar 23	James M Frates	Stock Option Common Stock	Grant	Acquire A	No	No	32.08	97,500	3.13 mm	97,500